IL-22-induced JAK/STAT signaling was clearly implicated in the regulation of MUC1 and MUC13 expression, further suggesting a potential use of JAK inhibitors to interfere with aberrant mucin expression and subsequent barrier function in the inflamed mucosa of IBD patients, as has also been highlighted in other diseases including cancer and COVID-19 [63,64,65,66,67]. Here, MUC13 is linked to inflammatory bowel disease.